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Botulinum neurotoxin serotype A is the most lethal of
all known toxins. Here, we report the crystal structure,
along with SAR data, of the zinc metalloprotease do-
main of BoNT/A bound to a potent peptidomimetic in-
hibitor (Ki = 41 nM) that resembles the local sequence
of the SNAP-25 substrate. Surprisingly, the inhibitor
adopts a helical conformation around the cleavage
site, in contrast to the extended conformation of the
native substrate. The backbone of the inhibitor’s P1
residue displaces the putative catalytic water mole-
cule and concomitantly interacts with the ‘‘proton
shuttle’’ E224. This mechanism of inhibition is aided
by residue contacts in the conserved S10 pocket of
the substrate binding cleft and by the induction of
new hydrophobic pockets, which are not present in
the apo form, especially for the P20 residue of the
inhibitor. Our inhibitor is specific for BoNT/A as it
does not inhibit other BoNT serotypes or thermolysin.
INTRODUCTION
Neurotoxins produced by the genus Clostridium are potent
chemodenervating zinc-dependent proteases that prevent the
Ca2+-triggered release of acetylcholine in neuromuscular junc-
tions by cleaving one of three SNARE proteins (Schiavo et al.,
1992; Blasi et al., 1993a, 1993b). Hydrolysis of these target pro-
teins renders them noncompetent for facilitating the membrane
fusion step that takes place before acetylcholine release in the
synaptic cleft. Because their use as therapeutic and cosmetic
agents has become increasingly widespread, a concomitant
increased risk of accidental overdosing can be expected. In
addition, since botulinum neurotoxins (BoNTs) can be easily pro-
duced and delivered via aerosol medium, these agents are con-
sidered to be among themost deadly of all potential bioweapons
(Josko, 2004). Therefore, the need for potent and effective inhib-
itors is a high priority. In this regard, peptidomimetics and hy-1588 Structure 16, 1588–1597, October 8, 2008 ª2008 Elsevier Ltddroxamic acid-based inhibitors have been developed that dis-
play inhibitory effects in the high nM range for the light chain of
the BoNT serotype A (BoNT/A LC) (Boldt et al., 2006; Burnett
et al., 2007; Kumaran et al., 2008; Silvaggi et al., 2008). Com-
pounds that contain zinc-coordinating sulfhydryl moieties might
potentially inhibit host zinc proteases thereby making them poor
therapeutic leads. The characteristically poor pharmacokinetics
of hydroxamates, their instability, and their reported toxicity,
which is likely due to their inhibition of an array of metallopro-
teases, also make them problematic as therapeutic agents (Rao,
2005; Suzuki and Miyata, 2005).
In this study, we report the crystal structure of a tight complex
between an active form of BoNT/A LC and a pseudopeptide
inhibitor that mimics the 7-residue QRATKML sequence of the
206-residue SNAP-25, the natural substrate of the BoNT/A LC
(Blasi et al., 1993a), near the cleavage site (Figures 1A and 1B).
This inhibitor, referred herein as I1, is the most potent non-zinc-
chelating, non-hydroxamate-based antagonist reported to date,
with a Ki = 41 nM. When tested against serotypes B, D, E, F, and
thermolysin, I1 did not display any detectable inhibition in our
assays, indicating that its inhibitory action is BoNT/A specific.
Our structure reveals a 310 helical backbone conformation for
the peptide inhibitor bound to the active site of BoNT/A LC.
This is in sharp contrast to the extended conformation of bound
SNAP-25 observed in the BoNT/A LC[E224Q,Y366F]:SNAP-25
complex (Breidenbach and Brunger, 2004). The inhibitor induces
binding pockets in BoNT/A LC that are not found in either the apo
BoNT/A LCor the BoNT/A LC[E224Q,Y366F]:SNAP-25 complex.
The information gained from these new, induced pockets, to-
gether with additional binding surfaces identified in the vicinity
of the I1-binding sites,will be useful for thedevelopment of effica-
cious antibotulinum drugs.
RESULTS AND DISCUSSION
The crystal structures of both free and I1-bound wild-type BoNT/
A LCs were determined by molecular replacement (see Table 1
and Experimental Procedures). All seven residues of the I1 inhib-
itor could be readily assigned on the basis of the highly interpret-
able, observed difference electron-density map (Figure 1C). TheAll rights reserved
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the conformation of the zinc-coordinating residues in the active
site of I1-bound BoNT/A LC, remain essentially unaltered relative
to the apo form of the protease crystallized under the same con-
ditions. This is indicated by an RMSD of 0.83 A˚ over all a carbons
of both structures of the enzyme, as well as by comparisons to
other reported BoNT/A LC structures (Figure 2).Nonetheless,
binding of I1 is accompanied by significant conformational
changes in the 60, 250, and 370 loops, confirming an observa-
tion that the BoNT/A LC active site has a high degree of ‘‘plastic-
ity,’’ as proposed previously (Kukreja and Singh, 2005; Burnett
et al., 2007; Silvaggi et al., 2007). With respect to bound I1, the
P20-P50 residues adopt a compact, 310 helical conformation,
with the backbone oriented such that its analogous scissile
bond (i.e., the bond between the P1-P10 residues) is buried
deep within the active site, close to the zinc ion. The remainder
of the inhibitor backbone chain orients toward the solvent-
exposed surface of the protease (Figure 3A).
Binding Determinants in the BoNT/A LC:I1 Complex
Our structure reveals that I1 induces conformational changes in
the active site of BoNT/A LC upon binding, as detailed below.
Strikingly, when the apoenzyme and I1-bound BoNT/A LC struc-
Figure 1. Two-Dimensional Structure and
Electron Density for I1
(A) One-letter code sequence for the 22 C-terminal
residues of the human SNAP-25 consisting of
206 residues. The 7-residue peptide sequence
(Q197-L203) of SNAP-25 used to design I1 and
its variants is shown in bold, and their correspond-
ing positions in the inhibitor indicated as P1-P60.
The amino terminus is indicated.
(B) Schematic representation of the I1 inhibitor.
Residues Q197, A199, and K201 in the Q197-
L203 peptide have been replaced by DNP-DAB,
Trp, andDAB, respectively. DNP-DAB: 4-(2,4-dini-
trophenylamino)-2-amino-butanoic acid; DAB:
2,4-diaminobutanoic acid. In both panels, the scis-
sile peptide bond is indicated by a thick, red line.
(C) View of a sA-weighted Fo-Fc electron-density
map contoured at 1.8s (graymesh) around I1 over-
laid with the refined model of the complex (I1 in
gray sticks and BoNT/A LC in tan ribbon represen-
tation). This map was computed with phases cal-
culated prior to the inclusion of the I1 inhibitor
(i.e., it is a model-bias free map).
tures are superimposed, steric clashes
are readily observed between the Trp,
Thr, and Leu residues of the inhibitor
(positions P20, P30, and P60, respectively)
and their complementary apoenzyme
residues (Figure 4).
The observed induced fit rationalizes
the relatively high affinity of I1 (Ki = 41 nM;
Table 2), especially when interpreted in
context with inhibition data from inhibitor
variants. To exemplify, the polar nitro and
butanoic acid groups on the inhibitor’s
aromatic P1 residue stabilizes a network
of hydrogen bonds with solvent and the backbone amide group
of the BoNT/A LC residue S259 (Figure 3B). The presence of
these stabilizing hydrogen bonds is consistent with the observa-
tion that a Phe, Gln, or Gly in this position (Table 2; peptides I6, I2,
and I7, respectively) results in decreased inhibition (Ki values of
8.3, 6.5, and 3.3 mM, respectively). Specifically, these peptides
lack the isosteric polarity of the 4-(2,4-dinitrophenylamino)-2-di-
amino-butanoic acid (DNP-DAB) group (Table 2; peptides I8 and
I1 with Ki values of 0.98 and 0.041 mM, respectively) and, hence,
the ability to make critical polar/ionic interactions with solvent
and BoNT/A LC residue S259.
The P10 residue of I1 establishes a critical anchoring neighbor-
ing point in the BoNT/A LC binding cleft. The side chain of P10 Arg
is projected into a deep pocket of the cleft (Figure 3C), where it
engages in a salt bridge with the side chain of D370. For this in-
teraction to be possible, the 370 loop of BoNT/A LC undergoes
a major conformational rearrangement such that the side chain
of D370, which is solvent exposed in the apo form, reorients
into the active site. This reorientation is stabilized by a hydrogen
bond between the side chain hydroxyl group of the I1 P30 Thr res-
idue and the carboxylate group of BoNT/A LC D370, while the
guanidinium group of I1 P10 Arg is also in close proximity to the
aromatic ring of BoNT/A LC F194, suggesting that cation-p
Structure 16, 1588–1597, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1589
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Potent Peptidomimetic Inhibitor of BoNT/A LCinteractions may further stabilize this orientation. Interestingly,
a similar binding mode has been reported for an arginine hydrox-
amate (Arg-HX) inhibitor in complex with BoNT/A LC (Silvaggi
et al., 2007).
A second, extensive anchoring contact that enhances the
binding of I1 to the active site is the P20 Trp, which docks to an
induced hydrophobic pocket composed of side chains V245,
L256, V258, Y366, L367, and F369, with the latter oriented
such that aromatic ring p-stacking is facilitated (Figure 3D). In
addition, the Trp indole ring nitrogen forms a hydrogen bond
with the backbone carbonyl of E257. In this pocket, the side
chain of F369 is repositioned relative to the apo form of BoNT/
A LC, which is accompanied by a conformational change of
the 370 loop. In addition, residue L367 is displaced to accommo-
date the I1 Trp side chain. Taken together, this induced fit to I1’s
steric and chemical complementarity may signify the existence
of a structural ‘‘Achilles tendon’’ in the BoNT/A LC protease, sug-
Table 1. X-Ray Data Collection and Refinement
Crystallographic Data
BoNT/A LC BoNT/A LC:I1
Space group P21212 P21212
a, b, c (A˚) 56.8, 191.1, 42.1 58.8, 189.2, 42.3
Resolution (A˚) 451.9
(1.981.90)
361.9
(1.981.90)
Unique reflections 46184 42358
Redundancy 4.2 (3.6) 5.9 (5.8)
Completeness (%) 95.9 (95.1) 76.1 (88.1)
I/s 17.1 (1.3) 14.9 (2.8)
Rsym
a (%) 9.5% (95.8%) 10.1% (53%)
Refinement
BoNT/A LC BoNT/A LC:I1
Resolution (A˚) 451.9 361.9
Rcryst/Rfree
b,c 18.0% / 24.3% 21.2% / 24.7%
No. atoms
BoNT/A LC 3196 3225
I1 Na 75
Ni 1 1
Zn 1 1
Water 250 232
Average thermal (B) factor
BoNT/A LC 29.2 A˚2 26.7 A˚2
I1 Na 27.9 A˚2
Ni 20.3 A˚2 23.9 A˚2
Zn 18.4 A˚2 18.2 A˚2
Water 37.7 A˚2 32.3 A˚2
Rmsds
Average bond length deviation 0.004 A˚ 0.007 A˚
Average bond angle deviation 0.84 1.0
Values in parentheses are for the high-resolution bin.
a Rsym =
P
h
P
iIi(h)  < I(h) > /
P
h
P
iIi(h), where Ii(h) is the i
th measurement
and < I(h) > is the mean of all measurements of I(h) for Miller indices h.
b Rcryst =
PjFobs  kFcalcj/
P
Fobs
c Free R value is the R value obtained for a test set of reflection (5% of
total) not used during refinement.1590 Structure 16, 1588–1597, October 8, 2008 ª2008 Elsevier Ltdgesting a diversity of strategies for structure-based inhibitor
development by making use of new induced pockets in the
active site.
The binding mode for P20 Trp provides a qualitative explana-
tion for the weaker inhibitory potencies of related pseudopeptide
derivatives. In particular, when the wild-type SNAP-25 Ala is
present in the P20 position (Table 2; peptide I8), the Ki is increased
by a factor of 25 relative to I1. This can be attributed to reduced
favorable hydrophobic interactions with the smaller methyl
group. Similarly, with I11, a Phe residue in this position is also
not as favorable as Trp, indicated by only an 8-fold increase in
Ki, compared with I1. It might be argued that a fraction of these
reductions can be attributed to the Lys substitution in position
P40, but this substitution has only a minor effect on inhibitory ac-
tivity (Ki increase of2.5 fold relative to I1). We estimated the ef-
fect of the Lys substitution by comparing peptides I9 and I10 and
from the observation that a BZA substitution in position P20 has
no statistically significant effect on Ki (compare I1 and I10).
The P20 Trp also induces a pocket for the adjacent P30 Thr of I1.
Specifically, the P30 Thr side chain points into the substrate-bind-
ing cleft, where its hydroxyl moiety engages in a hydrogen bond
with the D370 side chain carboxylate (Figure 3C), and its methyl
group makes hydrophobic contacts with the V70 side chain.
Of further importance for the affinity of I1 are the P40 2,4-diami-
nobutanoic acid (DAB) contacts with BoNT/A LC, and intrapep-
tide contacts with the methylenes of P1 DNP-DAB (Figure 3E).
The free terminal 4-amino substituent engages in a hydrogen
bond with the side chain carboxyl oxygen of Q162. This interac-
tion provides structure-based explanations for the inhibition data
of similar analogs (Table 2). In one example, increasing the length
of the DAB side chain by a longer ornithine side chain is sterically
unfavorable, resulting in a 2-fold decrease in inhibition (Table 2;
peptide I12). Likewise, the structure suggests why decreasing
the DAB side chain length decreases inhibition. This is exempli-
fied in the 2,3-diaminopropanoic acid (DAP) derivative that
possesses a Ki that is one order of magnitude larger than that
of I1 (see Table 2; derivative I13). This decreased inhibition can
be explained by the lost hydrogen bond with Q162 (Figure 3E).
Unlike most other residue positions in I1, the P50 Met only en-
gages in intrapeptide binding contacts (Figure 3A). Specifically,
this residue stabilizes the intramolecular hydrophobic collapse
of the aromatic ring of the P1 DNP-DAB. The Leu in position
P60 induces a conformational change in the 60 loop (Figure 4).
In particular, the side chain of residue R66 is slightly displaced
relative to its position in the apoenzyme, relieving steric clashes
with the terminal carboxyl group and electrostatic repulsions
with the synthetically added C-terminal amide of this residue.
Inhibition Mechanism
The mechanism for peptide cleavage employed by the BoNT/A
LC is believed to be similar to that of thermolysin, as supported
by several structural and mutagenesis studies (Li et al., 2000;
Binz et al., 2002; Agarwal et al., 2004; Swaminathan et al.,
2004) (Figures 5A–C). In this model, the geometry of the zinc
ion coordination in the active site changes upon SNAP-25 bind-
ing, such that the catalytic water is displaced by the carbonyl ox-
ygen in the P1 position (i.e., Q197) of the substrate and placed in
proximity to the carboxylate group of the putative ‘‘proton shut-
tle,’’ E224 (Figure 5A). As a result, the catalytic water makes twoAll rights reserved
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Potent Peptidomimetic Inhibitor of BoNT/A LCH-bondswith E224 in a bidentatemanner. From this position, the
oxygen atom in the catalytic water remains weakly coordinated
to the zinc, resulting in the penta-coordination of the metal ion.
Hence, E224 acts as a general base to generate a hydroxide
ion that is oriented for nucleophilic attack on the carbonyl carbon
of the scissile peptide bond (Figure 5B). This tetrahedral interme-
diate state is stabilized by putative interactions provided by the
zinc ion and the hydroxyl group of Y366. Finally, the collapse
of this tetrahedral intermediate and the E224-mediated transfer
of two protons onto the scissile amide generate a stable amino
group that then leaves the active site (Figure 5C). In this model,
the catalytic water, together with the proton shuttle E224, are
of critical importance for catalytic hydrolysis of the peptide
bond in the SNAP-25 substrate.
Consistent with this model, the structure of the BoNT/A LC:I1
complex shows that the carbonyl oxygen of P1 DNP-DAB is
indeed acting as the fourth zinc-coordinating group in the com-
plex, instead of the catalytic water molecule (Lacy et al., 1998),
a feature that has been previously reported for small molecule
hydroxamate inhibitors in complex with the BoNT/A LC
Figure 2. Superposition of BoNT/A Crystal
Structures
(A) Comparison of the backbone trace of reported
crystal structures of BoNT/A LC. The apo form of
wild-type BoNT/A obtained in the presence of
NiCl2 is colored magenta; wild-type BoNT/A LC
in complex with I1 is colored tan; the apo form of
the wild-type BoNT/A LC obtained in the absence
of NiCl2 is colored red (Burnett et al., 2007) (PDB
ID: 2ISE); the SNAP-25-bound form of the
E224Q/Y366F BoNT/A LC is colored gray (Brei-
denbach and Brunger, 2004) (PDB ID: 1XTG); the
ArgHX-bound form of the wild-type BoNT/A LC
is colored green (Silvaggi et al., 2007) (PDB ID:
2IMB). Flexible loops are labeled.
(B–E) Enlargements of the superposition of the 60,
200, 250, and 350 loops, respectively.
(F) Superposition of the zinc-coordinating residues
(sticks) as well as R363 and Y366 in all five struc-
tures indicated above.
(Fu et al., 2006; Silvaggi et al., 2007) (Fig-
ure 5D; Figure 6). In addition, the complex
structure also confirms the proposed hy-
drogen bonding between the hydroxyl
group of the Y366 side chain in the
BoNT/A LC, and the P1 carbonyl oxygen
(Figures 3B and 5D). Nonetheless, the
P1N-terminal aminogroup formsahydro-
gen bond with the carboxylate group of
E224, the putative proton shuttle residue
in the BoNT/A LC (Li et al., 2000), effec-
tively abrogating any interaction between
E224 and a potential catalytic water mol-
ecule (Figures 3B, 5D, and 6). Thus, E224
is clearly not positioned for a potential nu-
cleophilic attack on the scissile carbonyl.
In addition to this proton shuttle ‘‘block-
ing’’ effect, the putative scissile amide in
position P10 in the inhibitor is distant from the E224 carboxylate
group, further hampering any hydrolytic event with the scissile
bond. Consistent with this inhibitory role for the N-terminal amino
group in I1, similar pseudopeptide derivatives, in which the
amino group in question has been eliminated, acetylated or con-
figurationally reoriented so that it cannot engage in this hydrogen
bond (Table 2; peptides I3, I4, and I5, respectively), show less
inhibition than the corresponding derivatives with a free amino
group (e.g., peptides I2 and I1).
The interactions observed for residues P10-P30 stabilize the
orientation of the backbone of residue P1 for inhibition at the ac-
tive site. Presumably, the binding mode of this P10-P30 peptide
segment would orient the backbone of any residue bearing
a free amino group (as explained above) in the P1 position
so as to achieve the inhibitory mode observed for DNP-DAB
in I1—that is, by occupying the position of the catalytic water.
In silico mutation of the DNP-DAB residue in the complex struc-
ture suggests that the backbone of a Gln residue in this position
would also be placed in the same inhibitory mode described for
DNP-DAB (not shown). In agreement with our model, a 7-residue
Structure 16, 1588–1597, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1591
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substrate (and, therefore, the Gln-Arg scissile peptide bond),
showed inhibitory activity with no detectable hydrolysis (see
Table 2; peptide I2), reinforcing the notion that the residue at
the P1 position of all inhibitors in Table 2 deactivates BoNT/A
LC by displacing the nucleophilic water and simultaneously
‘‘locking’’ the E224 proton shuttle.
To assesswhether the inhibitorymechanismof I1 is specific for
BoNT/A LC, we examined it against four other BoNT serotypes,
as well as against thermolysin. When BoNT serotypes B, D, E,
and F or thermolysin were incubated with hydrolyzable con-
structs of their respective substrates, the presence of I1 did not
have any inhibitory effects on the cleavage of these substrates
(Table 3). Thus, I1 is a highly specific inhibitor for the BoNT/A LC.
The I1 and SNAP-25 Binding Modes Differ
Normally, onemight assume that the conformation of peptidomi-
metics derived from the sequence of the native SNAP-25
substrate around the scissile bond should resemble that of
Figure 3. Interactions of I1 with BoNT/A LC
(A) Complex of I1 (sticks) with BoNT/A LC (gold
surface). The N and C termini of I1, as well as the
60, 250, and 370 loops are labeled.
(B) Interactions of I1 residue P1 with BoNT/A LC
(tan), water molecules (red spheres), and the zinc
ion.
(C) Interactions of the P10 (Arg) and P30 (Thr) resi-
dues of I1 with BoNT/LC (tan). Superimposed is
residue D370 of the apo form of the BoNT/A LC
(magenta).
(D) Interactions of I1 residue P20 (Trp) with BoNT/A
LC (tan). Superimposed is residue F369 of the apo
form of BoNT/A LC (magenta).
(E) Interactions of I1 residue P40 (DAB) with BoNT/
A LC andwith residue P1 (DNP-DAB) of I1. Van der
Waals interactions between DNP-DAB and DAB
side chain methylene groups are displayed as
gray dots. The N and C termini of the I1 inhibitor
are indicated by N and C, respectively.
In all panels, selected hydrogen bonds between
the protease and inhibitor residues are indicated
by gray dashes. C, N, and O atoms of I1 are
color-coded in the stick representations (gray,
blue, and red, respectively). Where shown, the
zinc ion is displayed as a blue sphere.
SNAP-25 in the substrate:enzyme com-
plex. However, and of interest froma gen-
eral structural point of view, comparison
of both BoNT/A LC complexes (i.e.,
wild-type BoNT/A LC: I1 and BoNT/A
LC[E224Q,Y366F]:SNAP-25) shows that
the closely SNAP-25-related I1 assumes
a compact, a-helical conformation that
maximizes its packing interactions with
the active site, while the corresponding
segment in SNAP-25 (i.e., QRATKML)
adopts an extended, b stranded confor-
mation (Figure 7). This striking observa-
tion suggests that the intrinsic plasticity
of active sites in proteases, which can be a limiting factor in
the development of specific inhibitors, can actually be overcome
by designing peptidomimetics whose structural conformation
differs significantly from the cognate substrate. Thus, although
the backbones of both, I1 and SNAP-25, have the same direc-
tionality (i.e., N to C terminus) relative to the active site of the
enzyme, I1, by virtue of its novel backbone orientation, is able
to induce pockets in the active site (described above) that are
not induced by SNAP-25. As an additional result of this unex-
pected new conformation of I1, the P50 Met is clearly unable to
establish the b-exosite contacts with BoNT/A LC residues
Y250 and F369 observed for the corresponding SNAP-25
M202 residue in the BoNT/A LC[E224Q,Y366F]:SNAP-25 com-
plex (Breidenbach and Brunger, 2004) (Figure 7B). Furthermore,
the backbone and side chains of BoNT/A LC residues Q67 and
V68 are displaced by the presence of the C-terminal Leu residue
in the I1 peptide, relative to the SNAP-25-bound form of BoNT/A
LC [E224Q,Y366F] (Figure 7B). Thus, these two residues are po-
sitioned toward a more solvent-exposed region in the I1-bound
1592 Structure 16, 1588–1597, October 8, 2008 ª2008 Elsevier Ltd All rights reserved
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point to the entrance of the binding site, in which case theywould
clash with the Leu residue in I1. Overall, these findings reveal
a very different binding mode for SNAP-25 substrate and I1 in-
hibitor. Furthermore, SAR (Schmidt and Bostian, 1997; Schmidt
et al., 1998) are also at odds with the assumption of a similar
binding mode (Table 2). For example, as discussed above, sub-
stitution of Ala (SNAP-25 sequence) with Trp in the P20 position of
the inhibitor significantly increases its Ki.
Figure 4. Induced-Fit Binding of I1 to the BoNT/A Active Site
View of the binding cleft of the BoNT/A LC (tan surface) in complex with inhib-
itor I1 (gray sticks). Inhibitor residues are indicated by their three-letter amino
acid code, with the exception of residues P1 and P40 (DNP-DAB and DAB,
respectively). The induced binding pocket is evidenced by the steric clashes
between the apo BoNT/A LC surface (magenta) with inhibitor residues Trp,
Thr, and Leu upon superposition (translucent overlaps indicated by the black
ovals).The P10 Arg of I1 probably binds to the native S10 site on BoNT/
A LC since the coordination of the scissile carbonyl oxygen in our
structure is consistent with the catalysis mechanism (Figures
5A–C). Furthermore, the Arg side chain contacts with D370
and F194 observed in our structure have also been reported
for the BoNT/A LC:ArgHX complex(Silvaggi et al., 2007). There-
fore, these two observations, together with mutagenesis data
that demonstrate the requirement of the BoNT/A LC for an Arg
residue in the P10 position (Schmidt et al., 1998), support the no-
tion that the binding site for the P10 I1 residue corresponds to the
S10 site in BoNT/A LC. The SNAP-25 contacts at the BoNT/A LC
exosites favor the extended conformation of the substrate chain
in the vicinity of the active site (i.e., the SNAP-25 scissile bond),
which otherwise would collapse into a compact, nonhydrolyz-
able structure. The extended conformation of BoNT/A LC bound
SNAP-25 ensures that the backbone amide group in the P10 po-
sition, and not the P1 amide group (as observed for the I1 inhib-
itor), is in a competent orientation for attack by the catalytic water
in the protease, resulting in the cleavage of the peptide bond.
A cocrystal structure of BoNT/A LC with a weakly inhibiting
(Ki = 1.9 mM) heptapeptide, N-Ac-CRATKML, has been recently
reported (Silvaggi et al., 2008). In this complex, the Cys Sg atom
directly coordinates the Zn2+ in the protease active site. Although
the backbone secondary structure and directionality of this pep-
tide is somewhat similar to that of I1, the direct coordination to
the Zn2+ results in very different peptide:protein interactions.
For the N-Ac-CRATKML peptide, the N-terminal acetyl group
partially occupies the S10 site in the enzyme, resulting in an al-
tered placement of the P10 Arg residue, which no longer makes
the salt bridge contact with D370, observed for I1. In addition,
the P20 Ala residue in the N-Ac-CRATKML peptide lacks many
of the interactions of the corresponding Trp sidechain in I1,
explaining in part the superior potency of I1 versus N-Ac-
CRATKML. For example, the small methyl side chain of the Ala
residue of N-Ac-CRATKML can only form limited hydrophobicTable 2. Inhibitor and Inhibition (Ki) Data
Inhibitor Inhibitor Sequencea,b,c Ki (mM) Std. Dev.
P1 P10 P20 P30 P40 P50 P60
I2 Q R A T K M L 6.5 0.19
I3 3-Phenylpropanoyl- R A T K M L >200
I4 N-Acetyl-F R A T K M L >200
I5 [D]F R A T K M L >200
I6 F R A T K M L 8.3 0.79
I7 G R A T K M L 3.3 0.12
I8 DNP-DAB R A T K M L 0.98 0.12
I9 DNP-DAB R BZA T K M L 0.094 0.015
I10 DNP-DAB R BZA T DAB M L 0.05 0.0073
I11 DNP-DAB R F T K M L 0.32 0.021
I12 DNP-DAB R W T ORN M L 0.1 0.023
I13 DNP-DAB R W T DAP M L 0.39 0.01
I1 DNP-DAB R W T DAB M L 0.041 0.0084
aAll peptides have a free amino group at the N terminus, unless noted otherwise, and the C terminus is amidated.
bNonstandard abbreviations: DNP-DAB, 4-(2,4-dinitrophenylamino)-2-amino-butanoic acid; ORN, ornithine; DAB, 2,4-diaminobutanoic acid; DAP,
2,3-diaminopropanoic acid; BZA, benzothien-3-yl-alanine.
c All amino acids are the [L] stereoisomer unless noted otherwise.
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(A–C) Schematic representation of a model for BoNT/A LC-catalyzed hydrolysis of SNAP-25. Atoms, bonds, and residue labels of the BoNT/A LC, SNAP-25
substrate, and the water molecules are shown in black, green, and red, respectively. Details are provided in the main text.
(D) Schematic representation of the interactions of the I1 inhibitor with residues in the active site of the BoNT/A LC. Atoms, bonds, and residue labels of the I1
inhibitor are shown in blue.contacts with the side chain of V258. By contrast, the analogous
Trp side chain of I1 forms highly favorable p-stacking between
its phenyl portion of the indole and the side chain of Phe369.
This interaction occurs in combination with favorable hydropho-
bic contacts formed with side chain of Leu256 for this same sub-
stituent. Anti to this interaction, the phenyl portion of the I1 Trp
indole also forms favorable hydrophobic contacts with the side
Figure 6. Inhibitory Interactions of I1
Coordination of the zinc ion in the presence of bound I1 (gray sticks). The pu-
tative scissile carbonyl oxygen (sC), scissile amide nitrogen (sN), and the ter-
minal NH3 group of I1 are labeled. BoNT/A LC residues are shown as tan
sticks. The side chains of Arg and DNP-DAB in I1 are also labeled. Interactions
are represented as dashes. N, C, and O atoms are color-coded in blue,
tan/gray, and red, respectively. The zinc ion is represented by a light blue
sphere.1594 Structure 16, 1588–1597, October 8, 2008 ª2008 Elsevier Ltdchain of L367. These contacts are further stabilized by favorable
acid-base interactions between the side chain NH of Trp and the
backbone carbonyl of E257, and hydrophobic complementarity
between I1 Trp Cb, Cg, and Cd1 atoms with aromatic atoms of
Y366. As highlighted by the marked differences between the
conformations of this region for the N-Ac-CRATKML:BoNT/A
LC and I1:BoNT/A LC structures, these key interactions induced
by I1 Trp provide novel, specific details to exploit in future struc-
ture-based discovery and design investigations.
Implications for BoNT/A LC Inhibitor Development
Our cocrystal provides a new paradigm for peptidomimetic in-
hibitor binding in the BoNT/A LC substrate cleft and rationalizes
the SAR of related derivatives. This can serve as the platform for
designing more-potent analogs with therapeutic viability. For
example, the helical nature of the I1 conformation implies that
peptidic cyclization in an isosteric manner would simultaneously
provide affinity and a feasible bioavailability component for
a peptide structure. The hydrolyzable components such as pep-
tide bonds could be systematically replaced with nonhydrolyz-
able isosteres.
Table 3. Specificity of I1 Inhibition
Protease Substrate
Substrate
Concentration
(mM) % Inhibition
BoNT/A SNAP-25, residues 187–203 400 >90
BoNT/B VAMP residues 1–94 20 0
BoNT/D VAMP residues 1–94 20 0
BoNT/E SNAP-25, residues 1–206 20 0
BoNT/F VAMP residues 1–94 20 0
Thermolysin Synthetic peptidea 500 0
The inhibitor concentration was 4 mM.
a The sequence of the synthetic peptide was KLSELDDRADALQAGAS.All rights reserved
Structure
Potent Peptidomimetic Inhibitor of BoNT/A LCFigure 7. Comparison of the I1 Conforma-
tion with that of SNAP-25
(A) Cartoon representation of the backbone of
BoNT/A LC-bound inhibitor I1 (left) and the Q197-
L203 fragment in BoNT/A LC-bound SNAP-25
(right). The backbones of the corresponding
BoNT/A LC structures were superimposed to pro-
duce the shownorientations of I1 and theSNAP-25
fragment. For clarity, the corresponding BoNT/A
LC structures are not shown. The identity of the
residues in both molecules is indicated by their
one-letter code, with the exception of residues
DABandDNP-DAB in I1. Side chains of all residues
are shown as sticks. N, C, O, and S atoms are
colored in blue, cyan, red, and yellow, respectively.
The Zn2+ is displayed as a gray sphere. Both
backbones display the same N-to-C terminus di-
rectionality indicated by the solid vertical arrow.
The dashed vertical line indicates the presence of
additional SNAP-25 residues on both ends of the
Q197-L203 fragment, which have been omitted
for clarity.
(B) Cartoon representation of the superposition
of the BoNT/A LC complexes with I1 and SNAP-
25 (tan and green cartoons, respectively). The
cartoon representation of I1 and the QRATKML
sequence in SNAP-25 are shown in gray and
red, respectively, with their N and C termini ap-
propriately indicated. Selected residues of the
BoNT/A LC forming part of the reported b-exosite
are shown as green sticks. Residues in the
60 loop of BoNT/A LC undergoing I1-induced
conformational changes are shown as tan sticks.
The side chains of the Met residues in I1 and
SNAP-25 are shown as sticks, with the sulfur
atom colored yellow. The Zn2+ is shown as a light
blue sphere.The cocrystal structure suggests modifications of I1 to further
enhance its potency. For example, removal or replacement of
the P60 Leu with an amphipathic bioisoteric moiety such as
a morpholino group would be expected to reduce the entropic
penalty associated with this hydrophobic residue so close to
the solvent-exposed area. Further inspection of the I1 binding
site reveals additional potential binding pockets that might be
available for other chemical substituents to be included in future
inhibitors. In particular, unexploited hydrophobic patches such
as the one formed by the I161 and F194 side chains or that
defined by the side chains of residues F196, T215, and V219,
provide areas where new hydrophobic functional groups could
be incorporated to increase inhibitor:enzyme hydrophobic bind-
ing. Superposition of these two patches in the apo and bound
forms of the enzyme suggest a high degree of rigidity for these
hydrophobic patch forming residues (RMSD < 0.15 A˚). Finally,
the hydrophobic pocket formed around the P20 Trp is an impor-
tant new site for exploiting additional contacts that could further
stabilize binding in this induced pocket.
In addition to strategies for the design of improved peptide-
based BoNT inhibitors, the a-helical conformation of bound I1Structure 16, 1588and its chemical contacts can be used as a template for design
of small molecule nonpeptidic inhibitors. This approach would
involve using the relative geometries and distances of the key
substituents of the inhibitor togenerate three-dimensional search
queries for database mining.
In summary, the BoNT/A LC:I1 complex reveals a binding con-
formation for BoNT inhibitors in the catalytic cleft of the BoNTA/
LC that is very different from that of SNAP-25 substrate. A key
feature of this new binding mode is the induction of new binding
pockets in the active site of BoNT/A LC. Our structure reveals
that the basis for inhibition of BoNT/A LC catalytic activity by I1
involves the displacement of the catalytic water molecule and in-
teractions with the side chain of E224 in the enzyme active site.
The BoNT/A LC residues observed to interact with the P10 Arg in
I1 likely correspond to the native S10 site of the enzyme. The
structure of the BoNT/A LC:I1 complex and the observation of
new induced binding pockets is a starting point for the rational
design of more potent peptidomimetic inhibitors that are active
in the sub nM range, and provides a new framework for the de-
velopment of nonpeptidic, non-zinc-coordinating, small mole-
cule inhibitors. Finally, the high specificity displayed by I1 against–1597, October 8, 2008 ª2008 Elsevier Ltd All rights reserved 1595
Structure
Potent Peptidomimetic Inhibitor of BoNT/A LCBoNT/A (Table 3) indicates that compounds designed to mimic
the interactions described for this inhibitor are likely to display
the same specificity, and therefore, little or no side effects on
related protease systems, a feature highly desirable in the devel-
opment of therapeutic drugs.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Details of the bacterial expression and purification of the active form of wild-
type BoNT/A LC used in this study have been previously described (Breiden-
bach and Brunger, 2004). Solutions of wild-type BoNTA-LC containing 20 mM
HEPES (pH 7.4) were adjusted to a final 50 mM protein concentration.
Crystallization and Data Collection
Crystals were obtained by using the hanging drop vapor diffusion method at
20C. Briefly, 3 ml of a 50 mM protein stock were mixed with 1 ml of the mother
liquor containing 0.1X PEG MME 2000, 5 mM NiCl2, and 100 mM HEPES
(pH 7.8). A layer of a 1:1 mixture of parafin:silicon oil was poured onto the
mother liquor present in the well. Crystals appeared after approximately
five days of incubation. In order to achieve the binding of the I1 inhibitor to
BoNT/A LC in a complex, the crystals generated above were soaked in 3 ml
drops of a 1mM I1 water solution for 5min at RT. Then, they were further trans-
ferred into a 3 ml drop of a 3 mM I1 solution. Five minutes after this second
soak, the crystals were directly transferred into a cryo-solution containing
25% (v/v) glycerol, 0.1 X PEGMME 2000, 5 mM NiCl2, and 100 mM HEPES
(pH 7.8), and then were frozen in liquid nitrogen. The diffraction data were col-
lected at beamline 9.1 of the SSRL (Stanford Synchrotron Radiation Labora-
tory) at a wavelength of 1 A˚ and at a temperature of 100K. The soaked crystals
belonged to the P21212 space group. Integration, indexing, and scaling of the
diffraction data was performed using the HKL2000 suite of programs (Otwi-
nowski and Minor, 1997).
Structure Determination and Refinement of the Wild-Type
BoNT/A LC
The coordinates in the 2ISG pdb file were used as the template for solving the
structure of the apo form of wild-type BoNT/A LC using the PHASERmodule in
CCP4i (McCoy et al., 2005). The calculated phases from the molecular re-
placement step allowed for the generation of a sA-weighted mFo-DFc electron
density that unambiguously indicated the presence of the Zn and the Ni ions.
Cross-validation was performed by excluding 5% of the diffraction data
throughout the entire refinement process. After a few refinement cycles using
Phenix (Adams et al., 2002), water molecules were added, and further refine-
ment calculations were performed, alternated with manual modeling in Coot
(Emsley and Cowtan, 2004). The quality of the final structure was assessed
by using MolProbity (Davis et al., 2007). Ramachandran analysis showed
that the apo BoNT/A LC had 96.4% residues in the favored region with only
0.26% outliers.
The Ni ion present in this crystal form of BoNT/A LC is coordinated by the
side chain amino group of K272 and the NE2 atom from H269 from one
BoNT/A LC molecule, and by the ND2 atom in the side chain amide group of
N410 from a BoNT/A LC molecule in the neighboring asymmetric unit, as
well as by three water molecules. Compared to other reported crystal struc-
tures of the BoNT/A LC that were obtained in the absence of Ni, this ion causes
the side chains of K272 and H269 to reorient into closer proximity. Neverthe-
less, the backbone atoms of the H269-K272 segment remain, overall, in the
same orientation in all BoNT/A LC structures. More importantly, these resi-
dues, and those in the vicinity, are distant from the active site and do not par-
ticipate in a direct interactions with the I1 inhibitor or its interacting residues.
Structure Determination and Refinement of the Wild-Type BoNT/A
LC-I1 Complex
The coordinates in the 1XTF pdb file were used as the search model to deter-
mine the structure of the wild-type BoNT/A LC-I1 complex by molecular
replacement. The sA-weighted mFo-DFc electron density map clearly indi-
cated the presence of I1 in the vicinity of the active site (Figure 1C). The coor-
dinates of the I1 inhibitor were then added to those of the BoNT/A LC in the1596 Structure 16, 1588–1597, October 8, 2008 ª2008 Elsevier Ltdstructure of the complex using Coot. Final refinement and modeling was per-
formed as with the apo form of the BoNT/A LC. The quality of the final structure
was assessed by using MolProbity. Ramachandran analysis showed that
the BoNT/A LC:I1 structure had 97.7% residues in the favored region with
no outliers.
Inhibitor Synthesis
Peptides and peptidomimetics were synthesized with a model 431A Peptide
Synthesizer from Applied Biosystems (Foster City, CA). Reagents and amino
acid intermediates were obtained from Applied Biosystems (Foster City,
CA), Bachem (King of Prussia, PA), and from EMD Biochemicals (La Jolla,
CA). All peptides were C-terminal amides. Inhibitors were purified by re-
verse-phase HPLC with gradients of dilute trifluoroacetic acid and acetonitrile
using equipment from Waters Associates (Milford, MA). Molecular weights of
the inhibitors were confirmed by mass spectrometry.
Determination of Ki Values
The protease activity of the BoNT/A LC in the presence of various concentra-
tions of inhibitors was determined as described previously for the holotoxin
(Schmidt and Bostian, 1997; Schmidt et al., 1998) with minor modifications.
To determine initial hydrolysis rates, assays were incubated at 37C for various
times, depending on substrate and inhibitor concentrations, such that less
than 10% of the substrate was hydrolyzed. Ki values of inhibitors were then
calculated from fractional inhibition determinations using the equation:
Ki = [I]  (F)[I] / (F)(1 + ([S] / Km)), where [I] and [S] are the concentrations of
inhibitor and substrate, respectively, and F is fractional inhibition (Segel, 1975).
Values are averages of at least three independent determinations, each in trip-
licate. As an inherent property of the inhibitor, Ki is independent of the sub-
strate used to determine it: Ki = [E][I] / [EI]. Nevertheless, the Ki for I1 in kinetic
assays with full-length SNAP-25 substrate was also determined and found to
be the same as for the method used by Schmidt et al. (1998). Measured Ki
values against BoNT/A LC and holotoxin BoNT/A are very similar for peptide
analogs similar to I1, so all inhibition assays were performed only against
BoNT/A LC.
Specificity of I1 Inhibition
The protease activity of various BoNT serotypes and thermolysin in the pres-
ence of I1 inhibitor was determined as described previously (Schmidt and
Bostian, 1997). BoNT/B LC was obtained from Leonard Smith (United States
Army Medical Research Institute of Infectious Diseases, Frederick, MD).
BoNT/F LC was provided by S. Swaminathan (Brookhaven National Labora-
tory, Upton, NY). BoNT/E LC was purchased from BB Tech (Dartmouth,
MA), and thermolysin was purchased from Sigma-Aldrich (St. Louis, MO).
The gene for BoNT/D LC chain was provided by Raymond Stevens (Scripps
Research Institute, La Jolla, CA). It was expressed and purified in the labora-
tory of J.J.S. (unpublished procedure). Recombinant VAMP (residues 1–94)
and full-length SNAP25 were cloned, expressed, and purified in the laboratory
of JJS (unpublished procedures). The peptide substrate for thermolysin was
produced with a model 431A peptide synthesizer from Applied Biosystems
(Foster City, CA), using chemicals and protocols obtained from the sameman-
ufacturer. The peptide was purified by reverse-phase HPLC using a gradient of
acetonitrile in 0.1% trifluoroacetic acid (TFA).
The figures were prepared using PyMol (http://www.pymol.org).
ACCESSION NUMBERS
The coordinates and structure factors have been deposited into PDB (ID 3DSE
for apo BoNT/A LC and PDB ID 3DS9 for the BoNT/A LC:I1 complex).
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